Neuland Laboratories to declare ₹34 dividend at AGM on Aug 4
Neuland Laboratories Limited has convened its 42nd Annual General Meeting for August 4, 2026, via video conferencing. The agenda includes adopting audited financial statements for FY26 and declaring a final dividend of ₹34 per share, subject to shareholder approval. Special business items feature the appointment of Dr. Mauricio Futran as a Non-Executive Non-Independent Director and the approval of commissions for Non-Executive Directors. Additionally, shareholders will ratify the remuneration of M/s. Nageswara Rao & Co., Cost Auditors, for the financial year ending March 31, 2027.

*this image is generated using AI for illustrative purposes only.
Neuland Laboratories Limited has scheduled its 42nd Annual General Meeting (AGM) for August 4, 2026, at 10:00 a.m. IST through Video Conferencing (VC) and Other Audio Visual Means (OAVM). The meeting will cover the adoption of audited financial statements for the financial year ended March 31, 2026, and the declaration of a final dividend. Shareholders will also consider the appointment of a new director and the ratification of remuneration for cost auditors.
The Board of Directors has recommended a final dividend of ₹34 per share, or 340%, for the financial year 2025-26. This dividend is payable on or after August 11, 2026, to members whose names appear on the Register of Members as of July 24, 2026, which serves as the record date. The dividend distribution is subject to approval by the shareholders at the AGM.
Special Business Agenda
The AGM will include special business items, primarily the appointment of Dr. Mauricio Futran (DIN: 11699767) as a Non-Executive Non-Independent Director of the Company. Dr. Futran, who was appointed as an Additional Director on May 12, 2026, brings over 40 years of experience in strategic process and product development. His appointment is liable to retire by rotation.
Shareholders will also vote on a resolution to pay commission to Non-Executive Directors, not exceeding 1% of the net profits of the Company for each year, for a period of five years commencing from the financial year 2026-27. Additionally, the meeting seeks approval for the payment of professional fees to Dr. Futran for his services on the Scientific Advisory Board and as a technical consultant.
Cost Auditor Ratification
Another key resolution involves the ratification of the remuneration of the Cost Auditors. The Board has approved the re-appointment of M/s. Nageswara Rao & Co., Cost Accountants, to audit the cost records for the financial year ending March 31, 2027. The ratification seeks approval for a remuneration of ₹4,00,000 plus applicable taxes and out-of-pocket expenses.
Key Meeting Details
| Event | Date | Time |
|---|---|---|
| Remote E-voting Start | August 1, 2026 | 9:00 a.m. IST |
| Remote E-voting End | August 3, 2026 | 5:00 p.m. IST |
| AGM Date | August 4, 2026 | 10:00 a.m. IST |
| Record Date | July 24, 2026 | — |
| Dividend Payment | On or after August 11, 2026 | — |
The facility for remote e-voting will be available to members holding shares as of July 28, 2026. The Company has engaged National Securities Depository Limited (NSDL) to facilitate the e-voting process. Members can attend the AGM virtually through the NSDL e-Voting system.
Historical Stock Returns for Neuland Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.18% | +2.73% | +13.49% | +32.03% | +62.98% | +786.09% |
How will Dr. Mauricio Futran's extensive experience in strategic process development influence Neuland Laboratories' R&D pipeline and future product launches?
What impact will the 340% dividend payout have on the company's retained earnings and its ability to fund future capital expenditures?
Will the approval of commissions for Non-Executive Directors up to 1% of net profits affect shareholder sentiment regarding corporate governance?































